RxDoctor Payments Data

Sherry Thomas, MD

Obstetrics & Gynecology · Westlake Village, CANPI 1932154580

Payments from drug & device makers

$35,720in general payments, 2019–2025

Across 129 payments — averaging $276.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$23K
  • Femselect Inc.$4K
  • Myovant Sciences Inc.$3K
  • Pfizer$2K
  • Mayne Pharma Commercial LLC$622
  • Therapeuticsmd, Inc.$463
  • plus $3K from 23 others
$117,533in research payments, 2019–2025

Across 34 payments — averaging $3456.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cook Research Incorporated$62K
  • Coloplast$40K
  • Pelvalon Inc.$12K
  • Boston Scientific$3K

What the payments were for

  • Consulting fees$25,74172%
  • Speaking & faculty fees$4,62513%
  • Travel & lodging$2561%
  • Food & beverage$4,86014%
  • Education$2391%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,720 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$294,686
Medicare patients
378
Services billed
2,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EstringEstradiol77$40,433
ImvexxyEstradiol85$32,722
MyrbetriqMirabegron34$26,474
Methenamine Hippurate352$25,098
Estradiol337$25,003
PremarinEstrogens, Conjugated37$16,247
GemtesaVibegron19$16,029
YuvafemEstradiol60$8,658
Clobetasol Propionate157$7,620
Estradiol (Twice Weekly)Estradiol98$7,389
Trospium Chloride ErTrospium Chloride35$4,817
Metronidazole74$3,624
Tacrolimus29$3,206
ProgesteroneProgesterone, Micronized58$3,036
Fosfomycin Tromethamine12$1,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEstring, Premarin$2,371$56,680114 claims
Therapeuticsmd, Inc.Imvexxy$463$32,72285 claims
Astellas Pharma US IncMyrbetriq$279$26,47434 claims
Sumitomo Pharma America, Inc.Gemtesa$16$16,02919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Westlake Village

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →